Market cap per employee, and rate of R&D spending, for large pharmaceutical companies

Among large bio-pharmaceutical firms, Gilead is an outlier in terms of market cap per employee.

The data is also presented in the table below.

Firm R&D spending as percent of 2011 2nd quarter revenue Market Cap, billions of USD (August 7, 2011) Number of Employees Mrk Cap /employees
Johnson & Johnson 11.3% $  171.90 115,000 $   1,494,783
Roche 17.9% $  146.50 80,653 $   1,816,423
Novartis 16.1% $  131.16 119,418 $   1,098,327
Pfizer 13.2% $  138.19 110,600 $   1,249,458
Merck 15.9% $  97.88 91,000 $   1,075,604
Sanofi 14.3% $  95.99 101,575 $    945,016
Abbott 10.8% $  77.74 90,000 $    863,778
AstraZeneca 12.9% $  60.22 61,100 $    985,597
Amgen 21.0% $ 48.16 17,100 $   2,816,374
BMS 17.0% $ 46.79 27,000 $   1,732,963
Lilly 20.2% $  41.95 38,065 $   1,102,062
Gilead 13.2% $  29.32 4,000 $   7,330,000

Leave a Reply

You must be logged in to post a comment.